

**SURVEILLANCE AFTER CHILDHOOD CANCER: ARE SURVIVORS WITH AN INCREASED RISK FOR  
CARDIOMYOPATHY REGULARLY FOLLOWED-UP?**

**SUPPLEMENT**

Table S1. Factors associated with long-term adherence to recommended surveillance among survivors at high risk for cardiomyopathy (n=873).

	Total number	Adherence, n (%)	Crude RR (95% CI)	Adjusted RR <sup>a</sup> (95% CI)
<b>Sex</b>				
Females (ref)	385	80 (20.8)	1	1
Males	488	53 (10.9)	0.52 (0.38 to 0.72)***	0.57 (0.41 to 0.79)**
<b>Age (years)</b>				
< 36	260	41 (15.8)	1	1
36-49	521	76 (14.6)	0.93 (0.65 to 1.31)	0.86 (0.58 to 1.28)
≥ 50	92	16 (17.4)	1.10 (0.65 to 1.87)	0.83 (0.46 to 1.50)
<b>Deprivation score</b>				
Quintiles 1 & 2 (ref)	338	55 (16.3)	1	1
Quintiles 3	204	29 (14.2)	0.87 (0.58 to 1.32)	0.91 (0.55 to 1.41)
Quintile 4	175	25 (14.3)	0.88 (0.57 to 1.36)	0.94 (0.61 to 1.44)
Quintile 5 (most deprived)	156	24 (15.4)	0.95 (0.61 to 1.47)	1.02 (0.66 to 1.59)
<b>Childhood cancer</b>				
Wilms Tumour (ref)	128	51 (14.8)	1	1
Neuroblastoma	62	12 (8.1)	0.54 (0.21 to 1.39)	0.59 (0.23 to 1.52)
Hodgkin's lymphoma	51	20 (15.7)	1.06 (0.49 to 2.26)	0.87 (0.40 to 1.89)
Non-Hodgkin's lymphoma	202	56 (11.4)	0.77 (0.44 to 1.35)	0.77 (0.42 to 1.40)
Soft tissue sarcoma	133	40 (16.5)	1.11 (0.63 to 1.96)	1.05 (0.60 to 1.84)
Bone sarcoma	194	82 (21.7)	1.46 (0.89 to 2.39)	1.28 (0.75 to 1.17)
CNS tumour	41	7 (4.9)	0.32 (0.08 to 1.35)	0.33 (0.08 to 1.36)
Other solid cancers <sup>b</sup>	62	26 (19.4)	1.30 (0.68 to 2.51)	1.26 (0.64 to 2.48)
<b>Age at diagnosis</b>				
< 5 years (ref)	283	30 (10.6)	1	1
≥ 5 years	590	103 (17.5)	1.65 (1.12 to 2.41)***	1.64 (1.08 to 2.48)*
<b>Anthracycline dose &gt;250 mg/m<sup>2</sup></b>				
No (ref)	124	19 (15.3)	1	-
Yes	749	114 (15.2)	0.99 (0.64 to 1.55)	-
<b>Cardiac radiation ≥ 30 Gy to ≥ 10% of the LV volume</b>				
No (ref)	741	113 (15.3)	1	-
Yes	132	20 (15.2)	1.00 (0.64 to 1.54)	-
<b>Second cancer</b>				
No (ref)	796	114 (14.3)	1	1
Yes	77	19 (24.7)	1.72 (1.13 to 2.64)*	1.49 (0.96 to 2.29)

CI, confidence interval; CNS, central nervous system; FDep, French deprivation index; NA, non-available; RR, relative risk; SD, standard deviation.

<sup>a</sup> Adjusted for all other variables in the multivariable modified Poisson regression model.

<sup>b</sup> Gonadal tumour, thyroid tumour, retinoblastoma and other types of carcinoma.

\*, p-value <0.05; \*\*, p-value <0.01; \*\*\*, p-value <0.001.

		<b>Anthracycline</b>			
		∅	0-100 mg/m <sup>2</sup>	100-250 mg/m <sup>2</sup>	≥ 250mg/m <sup>2</sup>
<b>Cardiac radiotherapy</b>	∅ or <30 Gy				<b>HIGH RISK</b>
	≥30 Gy on ]0-10%] of the volume of the LV			<b>HIGH RISK</b>	<b>HIGH RISK</b>
	≥30 Gy on ≥ 10% of the volume of the LV	<b>HIGH RISK</b>	<b>HIGH RISK</b>	<b>HIGH RISK</b>	<b>HIGH RISK</b>

Figure S1. Definition of survivors at high risk of cardiomyopathy.

LV, left ventricular.